Important - 16/3/26 - We are currently experiencing an unusually high volume of calls. Please try to call only if it is urgent for today. Thank you.
Important Change Regarding Hospital Requested Blood Test Appointments Burkholderia stabilis associated with non-sterile wipes Switchboard LGBTQIA+ Support Line New screening videos to make health information more accessible for people with learning disabilities MMRV Vaccinations Smear Test Drop-In Morning New British Sign Language (BSL) signed content on GOV.UK NHS Breast and NHS Cervical Screening Programmes HOPE Programme – Chronic Pain, Fatigue, Anxiety & Depression YDAS – Torbay Young Person’s Drug and Alcohol Service New dates added for TALKWORKS’ menopause course Asthma “September Surge” Vaccinations at School ⚠️Results Line Changes ⚠️ Mounjaro Prescribing in Devon Primary Care🚫 HOPE Course for Chronic Pain & Fatigue Peninsula Cancer Care Survey Carers Forum – Tuesday 13th May 2025 South West Bowel Cancer Screening Measuring Loneliness (INTERACT) Study Torbay Vaccine Service HOPE Programme for Low Level Anxiety and Depression STARFISH: Steroid Administration Routes For Idiopathic Sudden Sensorineural Hearing Loss IMPACT-1 Study for People Suffering with PTSD HOPE Programme Anxiety and Depression When can I get my Flu Vaccine? RSV Vaccination for Pregnant Women RSV Vaccine for Older Adults Children and Family Health Devon (CFHD) Silvercloud online mental wellbeing programmes Still Experiencing Pain After Knee Cartilage Operation? – METEOR2 Study TRI Drug and Alcohol Service Survey for Men Experiencing Grief and Loss Maternity Hotline Other options when we run out of routine GP appointments Veteran Friendly GP Practice Long Covid Awareness How to Submit a Medical Request Using Patient Triage Behind the Scenes of your General Practice Heat Health Advice Patient advice and messages for elective care waiting lists Hayfever treatment starts at home Torbay General Practice Parkrun Measles cases prompt MMR vaccine call Travelling Abroad
The British Menopause Society (BMS) have recently updated their recommendations for progesterone dosage in women using higher doses of oestrogen as part of their HRT. This does not apply to women only using vaginal oestrogen. High dose oestrogen is defined as:
As you may recall from when you started HRT, whenever we give oestrogen to women with a uterus (womb) it is very important that we give them progesterone alongside it. If we were to give oestrogen without progesterone the lining of the womb (endometrium) can thicken and over time this can lead to endometrial cancer. The progesterone protects the endometrium from this risk. Signs that would prompt us to consider investigations for endometrial cancer would be any bleeding that occurs over 12 months after your periods have stopped or a change in your bleeding pattern if you still have periods (more frequent, heavier, or prolonged bleeding).
As you may also remember the reason that we tend to use Utrogestan (also known as micronised progesterone) for the progesterone component is that the data suggests this carries very little or no increased risk in breast cancer.
The new BMS guidelines state:
“There are insufficient data to advise on endometrial cancer risk when micronised progesterone, at a dose used for low or standard dose estrogen, is used in combination with moderate or high dose estrogen. Until evidence relating to safety with moderate and high dose estrogen is available, a pragmatic approach needs to be considered, as the risk to breast tissue from increasing the progesterone dose is also unknown; the use of 200 mg as a continuous preparation [this means if you are taking it daily] and 300 mg as a sequential preparation [this means if you are taking it for 2 weeks out of every 4] should be offered if using high dose estrogen”.
In view of these new guidelines you have four options going forward:
In April 2023 there was a joint safety alert from the British Menopause Society Faculty of Sexual Reproductive Health, Royal Colleges of General Practitioners, and Royal Colleges of Obstetricians and Gynaecologists. This was regarding growing awareness that there were increasing numbers of women who were being started on high doses of oestrogen that exceeded product licenses. Oestrogen should not be regularly prescribed in doses higher than the upper limit listed and tested in clinical research. The British Menopause Society have produced this table detailing different preparations of oestrogen and when they would be considered to be ultra-low, low, standard, moderate or high dose, though please note that for women on oral oestrogen, decisions around prescribing can be more complex to take into account the risk of clotting:
| Ultra – Low dose | Low dose | Standard Dose | Moderate Dose | High Dose | |
| Oestrogel | ½ pump | 1 pump | 2 pumps | 3 pumps | 4 pumps |
| Sandrena | 0.25mg | 0.5mg | 1.0mg | 1.5-2.0mg | 3mg |
| Lenzetto spray | 1 spray | 2 sprays | 3 sprays | 4-5 sprays | 6 sprays* |
| Patch | 12.5µg | 25µg | 50 µg | 75 µg | 100µg |
| Oral estradiol | 0.5mg | 1.0mg | 2.0 µg | 3.0mg^ | 4.0mg^ |
* Off-license use ^ Off-license use – rarely required to achieve symptom control mg = milligrams µg = micrograms
We are aware that some private providers are happy to prescribe above the recommended limits of oestrogen, as documented above. In such a scenario, our practice policy is that we would no longer be able to prescribe anything that contributes even in part to this overall treatment dose as there could be a risk to your safety with long term use of doses above recommended guidelines.
If this applies to you and you have been prescribed higher than recommended doses of oestrogen, we would therefore ask you to source all your medication supply privately or failing this to reduce your prescribed oestrogen dose. If you are feeling unable to reduce your oestrogen dose, and are unable to fund this privately, please speak to us about the option of being referred into the NHS complex menopause clinic for further management as an NHS patient.
If you believe that you may be on a dose higher than this, or a combination of different Oestrogen products (this does not include vaginal oestrogen cream 0.1% or pessary 10mcg) then please do make an appointment with our clinical pharmacist so that we can go through the potential risks with you and help to make your HRT safe.
We have attached for your convenience a British Menopause Society News update and a link to the full technical statement is available on this website: https://thebms.org.uk/2023/04/joint-bms-fsrh-rcgp-rcog-sfe-and-rcn-womens-health-forum-safety-alert/
If you’d like to discuss this with your preferred GP or Prescribing Pharmacist, please fill in an online Triage Form and someone will get back to you to arrange this.